IGF-1 LR3 Administration Due to the lack of data from clinical research and the fact that IGF-1 LR3 is not an approved amino acid analog of insulin-like growth factor 1 for human use, there are no official recommendations on how and where to inject it
The 5/5 vial gives equal parts of each, which is the ratio most closely matched by the published 1:1 blend protocols
Some people do experience mild fatigue a few hours after treatment, but don't worrythis is actually a good sign
A low ratio might suggest that your body is using up its antioxidant stores faster than it can replenish them
Animals fed with excess iron demonstrate increased lipid peroxidation, BBB breakdown, altered mitochondrial dynamics, -amyloid deposition, tau hyperphosphorylation, and loss of dendritic spine densityreminiscent of AD pathology (Sripetchwandee et al., 2014, 2016)